Metabolic Diseases  >>  emapticap pegol (NOX E36)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emapticap pegol (NOX E36) / TME Pharma
NCT00976729: NOX-E36 First-in-Human (FIH) Study

Checkmark P1 data
Jul 2012 - Jul 2012: P1 data
Completed
1
72
Europe
NOX-E36, Placebo
TME Pharma AG
Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus, Systemic Lupus Erythematosus
12/09
12/09

Download Options